

HAEMONETICS®

Haemonetics 3rd Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website

February 6, 2017

Financial release accessible online

BRAINTREE, Mass., Feb. 6, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that third quarter and year-to-date fiscal year 2017 financial results are available on its Investor relations website.

The Company is posting this press release and, additionally, three presentation slides that will be referenced on its webcast to its Investor Relations website.

Direct link to **Earnings Release FY17 Q3**:

<https://haemonetics.gcs-web.com/static-files/63ef4ace-0066-48da-ac0e-56a08c7dd33a>

Direct link to **Three Presentation Slides That Will Be Referenced on the Webcast**:

<https://haemonetics.gcs-web.com/static-files/0b7a90d0-a70b-4c44-ae27-82b842c15c1b>

As previously announced, the Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on February 6, 2017. A live webcast of the call can be accessed on Haemonetics' investor relations website.

Direct link to **Conference Call Webcast**: <http://edge.media-server.com/m/p/s6y9gqek>

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at <http://www.haemonetics.com>.

INVESTOR CONTACT:

Gerry Gould, VP-Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com

MEDIA CONTACT:

Sandra Jesse, Executive VP
(781) 356-9253
sandra.jesse@haemonetics.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-2017-earnings-release-available-on-investor-relations-website-300402192.html>

SOURCE Haemonetics Corporation